HER-2/neu(2+)腔面型乳腺癌的HER-2基因扩增与TopⅡα蛋白及临床特征的关联性分析  

The clinicopathologic features of HER-2 gene amplification in HER-2/neu(2+) luminal breast cancer and the correlation with TopⅡα protein

作　　者：雷雨[1] 王永恒[1] 喻凤[1] 刘莹[1] 刘屹[1] 

机构地区：[1]陕西省人民医院肿瘤内科,西安7100680

出　　处：《癌症进展》2016年第10期1022-1024,共3页Oncology Progress

摘　　要：目的分析HER-2基因扩增与腔面型HER-2/neu(2+)乳腺浸润性导管癌的临床病理特征及TopⅡα蛋白的关系。方法运用FISH检测手段对68例雌激素受体(ER)/孕激素受体(PR)阳性的腔面型HER-2/neu(2+)乳腺浸润性导管癌标本进行检测;应用免疫组化法(IHC)对68例标本进行TopⅡα蛋白表达检测。结果 FISH检测结果显示,68例标本中,HER-2基因扩增为13例(19.1%);HER-2基因扩增在不同年龄、术后病理分期、淋巴结转移数目、Ki-67表达的患者之间差异无统计学意义;HER-2基因扩增病例中,TopⅡαⅠ级6例(46.2%),Ⅱ级6例(46.2%),Ⅲ级1例(7.7%),Ⅳ级0例。TopⅡα蛋白表达情况在有无HER-2基因扩增的乳腺癌间差异无统计学意义(Z=1.353,P=0.176)。结论在HER-2/neu(2+)腔面型乳腺癌中,HER-2基因扩增与年龄、术后病理分期、淋巴结转移数目、Ki-67表达和TopⅡα蛋白表达无关。Objective To analyze the clinicopathological features of HER-2 gene amplification in HER-2/neu （2＋） in-vasive ductal breast carcinoma and its correlation with TopIIαprotein. Method FISH was applied to detect the 68 speci-mens of HER-2/neu （2＋） invasive ductal breast carcinoma with positive estrogen （ER）/progesterone （PR）;Immunohisto-chemical assay was utilized to detect the expression of TopⅡαprotein. Result FISH results showed that, in the 68 speci-mens, HER-2 gene amplification was observed in 13 （19.1%）;There was no significant difference between the gene am-plification of HER-2 in patients with different age, postoperative pathological stage, number of lymph node metastasis, and Ki-67 expression;Among those who with HER-2 gene amplification, 6 （46.2%） showed Top IIαin level I, 6 （46.2%） had Top IIαin level II, and 1 （7.6%） was with Top IIαin level III, while 0 was with level IV, suggesting that HER-2 gene amplification was not correlated with TopIIαprotein expression （Z=1.353, P=0.176）. Conclusion In HER-2/neu （2＋） lu-minal breast cancer, the gene amplification of HER-2 was unrelated with age, postoperative pathological stage, number of lymph node metastasis, Ki-67 expression and TopIIαprotein expression.

关 键 词：乳腺癌 表皮生长因子受体2基因 病理学 临床 肿瘤分期 

分 类 号：R737.9[医药卫生—肿瘤]